Recent Advance in Colorectal Cancer Liver Metastases
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 15 February 2025 | Viewed by 45
Special Issue Editors
2. Cancer Research Program, Research Institute—McGill University Health Center, 1001 Blvd Décarie, Montréal, QC H4A 3J1, Canada
Interests: colorectal cancer liver metastases; liver metastasis; CRLM histologic growth patterns; precision oncology; neuroendocrine tumors; clinical research; liver ischemia/reperfusion injury; non-alcoholic liver disease; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals
2. Cancer Research Program, Research Institute—McGill University Health Center, 1001 Blvd Décarie, Montréal, QC H4A 3J1, Canada
Interests: colorectal cancer liver metastases; liver regeneration; liquid biopsy; tumor microenvironment; CRLM histologic growth patterns
Special Issue Information
Dear Colleagues,
Colorectal cancer liver metastases (CRLMs) represent a significant challenge in oncology due to their complex biology. The liver is the most common site of metastasis for colorectal cancer, necessitating intricate management strategies. This Special Issue of Cancers compiles cutting-edge research to advance the understanding and treatment of CRLMs.
CRLMs are often characterized by heterogeneous histological growth patterns (HGPs), most commonly desmoplastic HGPs, pushing HGPs, and replacement HGPs, significantly affecting prognosis. HGPs influence response to local ablative therapies, recurrence after surgical resection, and determine sensitivity to chemotherapy and anti-angiogenic therapy. Optimal oncologic management of CRLMs, therefore, involves a multimodal approach, including systemic chemotherapy, targeted therapies, locoregional therapies (i.e., hepatic artery infusional therapy, microwave or radiofrequency ablative treatment, stereotactic radiotherapy, transarterial chemoembolization or Yttrium-90 embolization) and surgical interventions, yet debates continue regarding perioperative treatment duration and the timing of interventions. This is further complicated by factors such as HGP and tumor mutational status and clinical decisions involving the need for a two-stage hepatectomy or regenerative procedure.
Current research focuses on identifying novel biomarkers for early detection, understanding the molecular pathways that drive metastatic spread, and developing targeted therapies to inhibit these pathways. For instance, recent advances in liquid biopsy techniques have significantly improved the precision of monitoring disease progression and detecting minimal residual disease.
Despite significant progress, many challenges remain, particularly in addressing treatment resistance and the heterogeneity of metastatic tumors. This Special Issue will highlight the latest advancements in understanding the biology of and clinical practices in managing CRLMs, focusing on novel diagnostic tools and emerging therapeutic approaches. By bringing together research from diverse disciplines, we aim to foster a comprehensive dialog leading to improved patient outcomes.
Dr. Peter Metrakos
Dr. Jennifer Kalil
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer liver metastases
- histological growth patterns
- chemotherapy optimization
- liver regeneration
- future liver remnant
- liquid biopsy
- treatment resistance
